Effect of Helicobacter pylori eradication on gastric precancerous lesions: A systematic review and meta-analysis

被引:24
作者
Zhu, Fangyuan [1 ]
Zhang, Xiaoze [1 ]
Li, Ping [1 ]
Zhu, Yaodong [1 ,2 ]
机构
[1] Med Univ Anhui, Dept Integrated Tradit & Western Med Oncol, Affiliated Hosp 1, Hefei, Peoples R China
[2] Med Univ Anhui, Dept Integrated Tradit & Western Med Oncol, Affiliated Hosp 1, 120 Wan Sui Rd, Hefei 230000, Peoples R China
基金
中国国家自然科学基金;
关键词
eradication; gastric precancerous lesions; Helicobacter pylori; meta-analysis; progression; INTESTINAL METAPLASIA; ATROPHIC GASTRITIS; FOLLOW-UP; DOUBLE-BLIND; HISTOLOGICAL-CHANGES; RANDOMIZED-TRIAL; CANCER; INFLAMMATION; CARCINOGENESIS; REVERSIBILITY;
D O I
10.1111/hel.13013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundThe question of whether eradication of Helicobacter pylori (Hp) can reverse gastric precancerous lesions, including intestinal metaplasia, remains uncertain, leading to ongoing debate. Therefore, a meta-analysis was performed to evaluate the effect of Hp eradication on gastric precancerous lesions. Materials and MethodsPubMed, Embase, Cochrane Library, Web of Science, Scopus database, and were systematically searched from inception to April 2023 for studies that explored the impact of Hp eradication on gastric precancerous lesions. Risk ratios (RRs) and their 95% confidence intervals (95% CIs) were selected as the effect size. We used the random-effects model to assess pooled data. We also performed quality assessments, subgroup analyses, and sensitivity analyses. ResultsFifteen studies were included. Compared with placebo, Hp eradication could significantly prevent the progression of gastric precancerous lesions (RR = 0.87, 95% CI: 0.81-0.94, p < 0.01) and reverse them (RR = 1.32, 95% CI: 1.17-1.50, p < 0.01). Then, specific precancerous lesions were further explored. The progression of intestinal metaplasia was significantly prevented by Hp eradication compared to placebo or no treatment (RR = 0.80, 95% CI: 0.69-0.94, p < 0.01). Moreover, compared with placebo or no treatment, Hp eradication also improved chronic atrophic gastritis (RR = 1.84, 95% CI: 1.30-2.61, p < 0.01) and intestinal metaplasia (RR = 1.41, 95% CI: 1.15-1.73, p < 0.01). However, in terms of preventing dysplasia progression (RR = 0.86, 95% CI: 0.37-2.00) and improving dysplasia (RR = 0.89, 95% CI: 0.47-1.70), Hp eradication had no advantage compared to placebo or no treatment. ConclusionsHp eradication therapy could prevent the progression of gastric precancerous lesions and reverse them. Notably, intestinal metaplasia can be reversed, but this may only be appropriate for patients with epigenetic alterations and milder lesions.
引用
收藏
页数:14
相关论文
共 61 条
[1]   Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies [J].
Adamu, Mariam Abdullahi ;
Weck, Melanie Nicole ;
Gao, Lei ;
Brenner, Hermann .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2010, 25 (07) :439-448
[2]   Helicobacter pylori eradication in the healing of atrophic gastritis:: A one-year prospective study [J].
Arkkila, PET ;
Seppälä, K ;
Färkkilä, MA ;
Veijola, L ;
Sipponen, P .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 (07) :782-790
[3]   Predictors for regression and progression of intestinal metaplasia (IM): A large population-based study from low prevalence area of gastric cancer (IM-predictor trial) [J].
Aumpan, Natsuda ;
Vilaichone, Ratha-korn ;
Pornthisarn, Bubpha ;
Chonprasertsuk, Soonthorn ;
Siramolpiwat, Sith ;
Bhanthumkomol, Patommatat ;
Nunanan, Pongjarat ;
Issariyakulkarn, Navapan ;
Ratana-Amornpin, Sarita ;
Miftahussurur, Muhammad ;
Mahachai, Varocha ;
Yamaoka, Yoshio .
PLOS ONE, 2021, 16 (08)
[4]   Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis [J].
Chen, Hai-Ning ;
Wang, Zhu ;
Li, Xiao ;
Zhou, Zong-Guang .
GASTRIC CANCER, 2016, 19 (01) :166-175
[5]   Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer [J].
Cho, S. -J. ;
Choi, I. J. ;
Kook, M. -C. ;
Yoon, H. ;
Park, S. ;
Kim, C. G. ;
Lee, J. Y. ;
Lee, J. H. ;
Ryu, K. W. ;
Kim, Y. -W. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (05) :477-489
[6]   Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer [J].
Choi, Il Ju ;
Kook, Myeong-Cherl ;
Kim, Young-Il ;
Cho, Soo-Jeong ;
Lee, Jong Yeul ;
Kim, Chan Gyoo ;
Park, Boram ;
Nam, Byung-Ho .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) :1085-1095
[7]   Gut Microbial Dysbiosis and Changes in Fecal Metabolic Phenotype in Precancerous Lesions of Gastric Cancer Induced With N-Methyl-N′-Nitro-N-Nitrosoguanidine, Sodium Salicylate, Ranitidine, and Irregular Diet [J].
Chu, Fuhao ;
Li, Yicong ;
Meng, Xiangmei ;
Li, Yuan ;
Li, Tao ;
Zhai, Mengyin ;
Zheng, Haocheng ;
Xin, Tianxi ;
Su, Zeqi ;
Lin, Jie ;
Zhang, Ping ;
Ding, Xia .
FRONTIERS IN PHYSIOLOGY, 2021, 12
[8]   Chemoprevention of gastric dysplasia:: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy [J].
Correa, P ;
Fontham, ETH ;
Bravo, JC ;
Bravo, LE ;
Ruiz, B ;
Zarama, G ;
Realpe, JL ;
Malcom, GT ;
Li, D ;
Johnson, WD ;
Mera, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (23) :1881-1888
[9]  
CORREA P, 1990, CANCER RES, V50, P4737
[10]  
CORREA P, 1992, CANCER RES, V52, P6735